If you or a loved one is taking Tysabri, you may be wondering what tests are used to watch for progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that early detection through regular monitoring is critical for managing this rare brain infection. This guide explains the key follow-up exams and their role in patient safety.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). The FDA-approved prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. This pathway is supported by the observation that risk factors include the presence of anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label explicitly states that these factors should be considered when initiating or continuing therapy. Clinical presentation of PML typically includes subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on MRI findings of demyelinating lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequent reports of neurological symptoms that could overlap with PML, including fatigue (19,150 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they underscore the importance of prompt evaluation for any new or worsening neurological signs.
The timeline between Tysabri exposure and documented PML harm varies. Cases have been reported after a few months to several years of treatment, as noted in the label for herpes infections, but PML risk increases with cumulative exposure. The label advises withholding Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This underscores the need for vigilant monitoring throughout therapy. For patients in North Carolina who have developed PML after Tysabri use, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. Given that PML symptoms may develop insidiously, the discovery rule may apply, meaning the clock starts when the patient or a reasonable person would have connected the symptoms to Tysabri. However, this is a legal determination that depends on individual circumstances, and affected patients should consult with an attorney promptly to preserve their rights. Adequacy of warnings is a central issue in potential litigation. The Tysabri label includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and sign an enrollment form acknowledging risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether healthcare providers adequately communicated the risk of PML, especially given the severity and potential for fatal outcomes. The label states that PML usually leads to death or severe disability, and that risk factors should be weighed against expected benefit (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not fully informed of these risks, or if monitoring was insufficient, this could form the basis of a claim. In summary, Tysabri-associated PML is a serious adverse event with a known mechanistic basis and defined risk factors. Patients in North Carolina who have been harmed should be aware of the statute of limitations and the importance of timely legal consultation. The evidence supports that the drug's labeling includes explicit warnings, but the adequacy of communication and monitoring in individual cases may warrant further evaluation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, which may develop insidiously, the discovery rule may apply, meaning the clock starts when the patient or a reasonable person would have connected the symptoms to Tysabri. It is crucial to consult with an attorney promptly to preserve your rights.
Key risk factors include the presence of anti-JCV antibodies, longer treatment duration, and prior use of immunosuppressants. The FDA label explicitly states that these factors should be considered when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.